Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
CytoDyn to hold webcast to discuss leronlimab, recent charges against former CEO » 08:05
12/23/22
12/23
08:05
12/23/22
08:05
CYDY

CytoDyn

/

+

CytoDyn will hold a…

CytoDyn will hold a webcast on December 29, 2022 at 8:00 a.m. Pacific Time to discuss the performance of leronlimab in its clinical trials and the recent charges against its former CEO Nader Pourhassan, who was previously terminated on January 24, 2022, and has had no affiliation with the Company since that time.

ShowHide Related Items >><<
CYDY CytoDyn
/

+

Hot Stocks
Former CytoDyn CEO charged with scheme to defraud investors » 12:31
12/20/22
12/20
12:31
12/20/22
12:31
CYDY

CytoDyn

/

+

A federal grand jury in…

A federal grand jury in the District of Maryland returned an indictment that was unsealed today charging two men for their roles in schemes to defraud investors in CytoDyn (CYDN), the Department of Justice announced in a statement. According to court documents, Nader Pourhassan and Kazem Kazempour allegedly engaged in a conspiracy to defraud investors through false and misleading representations and material omissions relating to CytoDyn's development of leronlimab, a monoclonal antibody investigational drug also known as PRO 140, as a potential treatment for human immunodeficiency virus. Pourhassan and Kazempour allegedly deceived investors about the timeline and status of CytoDyn's regulatory submissions to the Food and Drug Administration to artificially inflate and maintain the price of CytoDyn's stock and attract new investors, the DOJ says. Pourhassan was CytoDyn's CEO at the time of the alleged fraud. Kazempour is the co-founder, president, and CEO of Amarex Clinical Research. Reference Link

ShowHide Related Items >><<
CYDY CytoDyn
/

+

Over a quarter ago
Hot Stocks
CytoDyn appoints Stephen Simes, Ryan Dunlap to board » 08:36
10/20/22
10/20
08:36
10/20/22
08:36
CYDY

CytoDyn

/

+

CytoDyn announced…

CytoDyn announced additional changes in its Board of Directors. Mr. Stephen Simes, a career public company biotech CEO, was appointed to the Board effective October 13, 2022. Mr. Ryan Dunlap, a current CFO with public company biotech experience, was appointed to the Board effective August 25, 2022. Mr. Simes and Mr. Dunlap join the Board as independent directors of the Company. Also, concurrently with the appointment of Mr. Simes, Dr. Scott Kelly resigned as a director. Dr. Kelly will continue to serve as the Company's Chief Medical Officer and Head of Business Development. The Board now has five directors, all of whom are independent directors.

ShowHide Related Items >><<
CYDY CytoDyn
/

+

Conference/Events
CytoDyn to hold an investment community webcast » 15:45
09/28/22
09/28
15:45
09/28/22
15:45
CYDY

CytoDyn

/

+

President Arman, CFO…

President Arman, CFO Migliarese and CMO Kelly hold an investment community webcast to provide a quarterly Company update on September 28 at 4 pm. Webcast Link

ShowHide Related Items >><<
CYDY CytoDyn
/

+

Conference/Events
CytoDyn to hold an investment community webcast » 12:20
09/28/22
09/28
12:20
09/28/22
12:20
CYDY

CytoDyn

/

+

President Arman, CFO…

President Arman, CFO Migliarese and CMO Kelly hold an investment community webcast to provide a quarterly Company update on September 28 at 4 pm. Webcast Link

ShowHide Related Items >><<
CYDY CytoDyn
/

+

Syndicate
CytoDyn files to sell 35.8M shares of common stock for holders  17:36
09/14/22
09/14
17:36
09/14/22
17:36
CYDY

CytoDyn

/

+

 
ShowHide Related Items >><<
CYDY CytoDyn
/

+

Syndicate
CytoDyn files to sell 208.7M shares of common stock for holders  17:55
08/23/22
08/23
17:55
08/23/22
17:55
CYDY

CytoDyn

/

+

 
ShowHide Related Items >><<
CYDY CytoDyn
/

+

Hot Stocks
CytoDyn appoints Arman as President » 08:41
07/13/22
07/13
08:41
07/13/22
08:41
CYDY

CytoDyn

/

+

CytoDyn announced the…

CytoDyn announced the appointment of Dr. Cyrus Arman as President effective July 9, 2022. Dr. Arman will be responsible for determining and leading the Company's operating strategy for the future. It is anticipated that he will advance to Chief Executive Officer and be appointed to the Board of Directors within six months. Antonio Migliarese, who had been serving as interim President since late January, in addition to CFO, will resume his previous role as CFO. Dr. Arman brings over 15 years of industry experience. Most recently, Dr. Arman served as Chief Business Officer for Nimble Therapeutics.

ShowHide Related Items >><<
CYDY CytoDyn
/

+

Hot Stocks
CytoDyn highlights NIH grant for HIV functional cure preclinical study » 08:42
07/11/22
07/11
08:42
07/11/22
08:42
CYDY

CytoDyn

/

+

CytoDyn announced a new,…

CytoDyn announced a new, preclinical study in nonhuman primates that will evaluate the potential use in HIV of a gene therapy based on the experimental monoclonal antibody leronlimab. The research will be led by Oregon Health & Science University researcher Jonah Sacha, Ph.D., who also serves as a CytoDyn scientific advisor. The study is funded by a five-year grant of up to $5 million to OHSU from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. The grant will fund the development and preclinical research of a single-injection gene therapy that codes for the leronlimab protein sequence and which will be delivered via an adeno-associated virus vector. The study will examine if this gene-therapy approach could provide the potential for "functional cure," i.e., sustained viral suppression to people with HIV without requiring them to take medications for the rest of their lives.

ShowHide Related Items >><<
CYDY CytoDyn
/

+

Hot Stocks
CytoDyn reaches non-cash settlement with former CMO Richard Pestell » 08:43
05/23/22
05/23
08:43
05/23/22
08:43
CYDY

CytoDyn

/

+

CytoDyn announced that it…

CytoDyn announced that it has reached a non-cash settlement with its former Chief Medical Officer Richard Pestell, concerning an ongoing legal dispute related to his former employment with the Company. Under the terms of the agreement, the parties will release each other of all claims, and the Company will release to Dr. Pestell 8.3M shares of the Company's common stock held in escrow, transfer to Dr. Pestell the assets acquired from ProstaGene LLC and subsequently written-off by the Company and issue a warrant at an exercise price of $0.37 per share to Dr. Pestell for seven million shares of the Company's common stock. Dr. Pestell and the Company are also exploring ways in which Dr. Pestell can reengage with the Company to help realize leronlimab's full potential in oncology. CytoDyn regrets Dr. Pestell's departure from the Company and the subsequent public statements made by its former CEO about Dr. Pestell.

ShowHide Related Items >><<
CYDY CytoDyn
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.